This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tournade, M. F. Articles by Zucker, J. M. Search for Related Content PubMed PubMed Citation Articles by Tournade, M. F. Articles by Zucker, J. M. Social Bookmarking                            What's this?

Optimal Duration of Preoperative Therapy in Unilateral and Nonmetastatic Wilms’ Tumor in Children Older Than 6 Months: Results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study

From the Institut Gustave-Roussy, Villejuif; Institut Curie and University Paris VI, Paris, France; Emma Kinderziekenhuis/Academish Medical Center, Amsterdam, the Netherlands; Division of Hematology and Oncology, Childrens’ Hospital, University of Heidelberg, Germany; Marciniak Hospital, Wroclow, Poland; Clinica Pediatrica dell’Università, Padova, Italy; and Universitätsklinik für Strahlentherapie and Biologie, Wien, Austria.

Address reprint requests to M.F. Tournade, MD, Institut Gustave-Roussy, Département de Pédiatrie, 39 Rue Camille Desmoulins, 94805 Villejuif, Cedex, France; email tournade{at}igr.fr

PURPOSE: To determine the optimal duration of preoperative chemotherapy to further increase the proportion of stage I tumors by comparison of two regimens in the treatment of patients older than 6 months who have unilateral Wilms’ tumor.

PATIENTS AND METHODS: Eligible patients (n = 382) initially received four weekly doses of vincristine (VCR) and two courses of actinomycin D (AMD) and were randomized either to be operated on (4-week group [n = 193]) or to receive 4 more weeks of the same chemotherapy regimen (8-week group [n = 189]). The assessment criterion was the observed percentage of stage I tumors. After surgery, patients were assigned according to tumor stage and histology to four different treatment groups: stage I and favorable histology (n = 5) were to have no further treatment (NFT); stage I and standard histology or anaplasia (n = 244), VCR and AMD for 17 weeks (AV); stages II and III and favorable or standard histology, VCR, AMD, and an anthracycline for 27 weeks (AVE) with no abdominal radiotherapy for stage II N0 disease (n = 75) or with a 15-Gy dose of abdominal irradiation (RTH) in case of stages IIN1 and III (n = 56). Anaplastic tumors staged higher than I or clear-cell sarcoma of the kidney (14), AMD, VCR, an anthracycline, and ifosfamide for 36 weeks (DEVI).

RESULTS: No advantage was found in favor of prolonged preoperative treatment. The percentages obtained for the 4-week and the 8-week groups, respectively, were as follows: stage I, 64% versus 62%; intraoperative tumor rupture rate, 1% versus 3%; 2-year EFS, 84% versus 83%; and 5-year OS, 92% versus 87%. Two-year EFS and 5-year OS rates, respectively, of the different treatment groups were as follows: NFT, 100% for both EFS and OS; AV, 88% and 93%; AVE, 84% and 88%; AVE RTH, 71% and 85%; and DEVI, 71% and 71%. The rate of abdominal recurrences in stage II N0 nonirradiated patients was 6.6%.

CONCLUSION: The 4-week schedule pre-nephrectomy chemotherapy regimen should be considered the standard treatment. Clinical trials should continue to improve the cure rate of high-risk patients and the quality of life of children with a more favorable prognosis.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. J. D'Angio Pre- or Postoperative Therapy for Wilms' Tumor? J. Clin. Oncol., September 1, 2008; 26(25): 4055 - 4057. [Full Text] [PDF]

				Y. Stewenius, Y. Jin, I. Ora, J. de Kraker, J. Bras, A. Frigyesi, J. Alumets, B. Sandstedt, A. K. Meeker, and D. Gisselsson Defective Chromosome Segregation and Telomere Dysfunction in Aggressive Wilms' Tumors Clin. Cancer Res., November 15, 2007; 13(22): 6593 - 6602. [Abstract] [Full Text] [PDF]

				M Tretiakova, M Turkyilmaz, T Grushko, M Kocherginsky, C Rubin, B Teh, and X J Yang Topoisomerase II{alpha} in Wilms' tumour: gene alterations and immunoexpression J. Clin. Pathol., December 1, 2006; 59(12): 1272 - 1277. [Abstract] [Full Text] [PDF]

				M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]

				G. J. Veal, M. Cole, J. Errington, A. Parry, J. Hale, A. D.J. Pearson, K. Howe, J. C. Chisholm, C. Beane, B. Brennan, et al. Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study Clin. Cancer Res., August 15, 2005; 11(16): 5893 - 5899. [Abstract] [Full Text] [PDF]

				C. Manzitti, P. Toma, A. Rizzo, C. Gambini, and A. Garaventa Problems in Colon Cancer and a Child With Renal Lymphoma: CASE 3. Mature B-Cell Renal Lymphoma Presenting As a Single Osseous Mass in a Child J. Clin. Oncol., August 1, 2005; 23(22): 5257 - 5259. [Full Text] [PDF]

				T. Schlomm, B. Gunawan, H.-J. Schulten, B. Sander, K. Thangavelu, N. Graf, I. Leuschner, R.-H. Ringert, and L. Fuzesi Effects of Chemotherapy on the Cytogenetic Constitution of Wilms' Tumor Clin. Cancer Res., June 15, 2005; 11(12): 4382 - 4387. [Abstract] [Full Text] [PDF]

				J. de Kraker and K. P. Jones Treatment of Wilms Tumor: An International Perspective J. Clin. Oncol., May 1, 2005; 23(13): 3156 - 3157. [Full Text] [PDF]

				D. Green In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3157 - 3158. [Full Text] [PDF]

				H. Reinhard, S. Aliani, C. Ruebe, M. Stockle, I. Leuschner, and N. Graf Wilms' Tumor in Adults: Results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study J. Clin. Oncol., November 15, 2004; 22(22): 4500 - 4506. [Abstract] [Full Text] [PDF]

				C. Jones, K. Pritchard-Jones, M. A. Ghanem, T. H. Van der Kwast, R. M. Nijman, and G. J. van Steenbrugge MIB-1 and p27Kip1 Expression in Nephroblastoma Clin. Cancer Res., November 15, 2004; 10(22): 7785 - 7786. [Full Text] [PDF]

				A. Weirich, R. Ludwig, N. Graf, U. Abel, I. Leuschner, G. M. Vujanic, O. Mehls, J. Boos, J. Beck, B. Royer-Pokora, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity Ann. Onc., May 1, 2004; 15(5): 808 - 820. [Abstract] [Full Text] [PDF]

				D. M. Green The Treatment of Stages I-IV Favorable Histology Wilms' Tumor J. Clin. Oncol., April 15, 2004; 22(8): 1366 - 1372. [Full Text] [PDF]

				N. L. Seibel, S. Li, N. E. Breslow, J. B. Beckwith, D. M. Green, G. M. Haase, M. L. Ritchey, P. R.M. Thomas, P. E. Grundy, J. Z. Finklestein, et al. Effect of Duration of Treatment on Treatment Outcome for Patients With Clear-Cell Sarcoma of the Kidney: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., February 1, 2004; 22(3): 468 - 473. [Abstract] [Full Text] [PDF]

				K. Pritchard-Jones, A. Kelsey, G. Vujanic, J. Imeson, C. Hutton, and C. Mitchell Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms' Tumor Treated With Vincristine Monochemotherapy: A Study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group J. Clin. Oncol., September 1, 2003; 21(17): 3269 - 3275. [Abstract] [Full Text] [PDF]

				K Pritchard-Jones Controversies and advances in the management of Wilms' tumour Arch. Dis. Child., September 1, 2002; 87(3): 241 - 244. [Abstract] [Full Text] [PDF]